Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 30, 2011 Brian Orelli	A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace.
The Motley Fool July 22, 2011 Brian Orelli	It's How You Finish That Matters Human Genome Sciences gained approval of the first drug developed for lupus in half a century, but in its first full quarter on the market Benlysta was uninspiring.
The Motley Fool November 17, 2010 Brian Orelli	52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval.
The Motley Fool July 20, 2009 Brian Orelli	Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.
The Motley Fool January 10, 2012 Brian Orelli	Linear Growth Isn't Enough Human Genome Sciences needs to accelerate growth.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool November 2, 2009 Brian Orelli	Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed.
The Motley Fool March 17, 2011 Brian Orelli	Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping.
The Motley Fool December 6, 2010 Brian Orelli	3-Month Delay? No Problem! Investors shrug off HGS' Benlysta delay. The Food and Drug Administration's delaying its decision on whether to approve Human Genome Sciences and GlaxoSmithKline's Benlysta shouldn't come as much of a surprise.
Chemistry World July 20, 2012 Andrew Turley	GSK secures $3.6bn HGS deal After months of wrangling, GlaxoSmithKline has found enough common ground with Human Genome Sciences for the two to sign up to a $3.6 billion takeover deal.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Lupus: How Big will Benlysta Become? Human Genome Sciences/GSK's Benlysta (belimumab) was approved by an FDA advisory committee in November -- to the cheers of many patients who had testified to their need of the novel therapy.
The Motley Fool October 30, 2009 Brian Orelli	Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening.
Chemistry World November 4, 2009 Phil Taylor	New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells.
The Motley Fool October 5, 2005 Stephen D. Simpson	Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart.
Chemistry World March 15, 2011 Sarah Houlton	Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration
The Motley Fool August 28, 2009 Brian Orelli	Is There Life After a 714% Return? It doesn't get any less risky for Immunomedics.
The Motley Fool October 28, 2011 Brian Orelli	Invest in Biotechs Going After Unmet Needs What a quarter it was for Vertex Pharmaceuticals: $420 million in net sales of its new hepatitis C drug.
The Motley Fool October 5, 2010 Brian Orelli	You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure.
The Motley Fool August 4, 2011 Brian Orelli	Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse?
The Motley Fool August 11, 2011 Brian Orelli	Dendreon's a Broken IPO, Again $10 isn't really a magical number.
The Motley Fool June 14, 2010 Brian Orelli	No Approval? No Problem! Investors shrug off Human Genome's news about its hepatitis C drug Zalbin.
The Motley Fool December 9, 2008 Brian Orelli	Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences.
The Motley Fool November 12, 2010 Brian Orelli	Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week.
The Motley Fool December 16, 2011 Brian Orelli	Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech.
The Motley Fool March 9, 2010 Brian Orelli	The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections.
The Motley Fool January 5, 2012 Brian Orelli	Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today.
The Motley Fool November 25, 2011 Brian Orelli	7 Black Friday Biotech Bargains Get in at the right time to maximize your returns.
The Motley Fool July 22, 2010 Rich Smith	This Just In: Upgrades and Downgrades Baird turns bullish on Human Genome Sciences.
The Motley Fool September 11, 2007 Brian Orelli	A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note.
The Motley Fool January 5, 2012 David Williamson	Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%.
The Motley Fool February 28, 2008 Brian Lawler	Too Much Hope in Human Genome Shares Human Genome announces its guidance for 2008. Investors, take note.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.
The Motley Fool September 30, 2011 David Williamson	This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more.
The Motley Fool December 6, 2011 Brian Orelli	Pfizer Faces Firing Line A panel of outside experts will help decide Inlyta's fate.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool August 5, 2011 Brian Orelli	Still Want to Be the Next Dendreon? The biotech market is punished.
The Motley Fool November 17, 2011 Brian Orelli	In Biotech, Approval's Important, but It's the Launch That Counts With an approval in hand, Incyte's investors are still nervous.
The Motley Fool January 10, 2012 Sean Williams	Could This Stock Nearly Double 2 Years In a Row? Up 96% in 2011, there's a decent chance at a Jazz Pharmaceuticals repeat in 2012.
The Motley Fool February 27, 2009 Brian Orelli	Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government.
Chemistry World February 4, 2009 Matt Wilkinson	GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus.
The Motley Fool November 30, 2011 David Williamson	Health Care's 5 Worst November Flops These stocks had a terrible month.
The Motley Fool August 31, 2007 Brian Orelli	Guidelines to Stop the Wheezing Investors, new asthma guidelines will affect some drug makers. The FDA isn't the only organization that affects how well drugs do in the marketplace.
The Motley Fool August 2, 2007 Brian Lawler	Human Genome Advances Human Genome Sciences updates investors on what to expect. The past quarter has been full of developments on their two lead drugs. Phase 3 studies for both are currently under way.
The Motley Fool January 8, 2008 Brian Orelli	A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain.
Science News March 28, 2009	Science Past For March 28, 1959 Thoughts on patient resocialization in a mental hospital during the 1950s.
The Motley Fool April 1, 2010 Rich Smith	This Just In: Upgrades and Downgrades Jesup and Collins are just a couple of fools in love ... with Human Genome Sciences.